



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

AB

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/155,514	11/17/1998	MIE KAINOH	1102-98	8751
35811	7590	12/21/2004	EXAMINER	
IP DEPARTMENT OF PIPER RUDNICK LLP ONE LIBERTY PLACE, SUITE 4900 1650 MARKET ST PHILADELPHIA, PA 19103			SCHWADRON, RONALD B	
		ART UNIT		PAPER NUMBER
				1644

DATE MAILED: 12/21/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER

ART UNIT PAPER

2001412

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

- a) The paper copy of the sequence listing lacks mandatory section <140>.
- b) The filing date in section <140> of the paper copy of the listing is incorrect and differs from that in the CRF (eg. it should be 11/17/98).
- c) The paper copy of the sequence listing was amended in the amendment filed 5/29/2001 wherein section <212> of SEQ. Ids 1,2 and 19 were changed to nucleic acid, yet the CRF recites DNA. In addition, said amendment changed portions of the listing to the preJuly 1998 format whilst the CRF is in the postJuly 1998 sequence rules format.
- d) In sequences 1,2,19,32-34, section <213> of the paper listing/CRF recites "homo sapien" when it should recite "artificial sequence". The aforesaid sequences are drawn to nucleic acids encoding proteins or said proteins wherein the molecules are Ig/integrin fusion proteins which are artificial sequences (eg. not found in nature).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Ron Schwadron, Ph.D.
Primary Examiner
Art Unit 1644
571 272 0851


RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800-1600